Universal Beteiligungs und Servicegesellschaft mbH Buys New Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired a new position in GoodRx Holdings, Inc. by purchasing 62,104 shares valued at approximately $274,000 during the first quarter of the year.
• Institutional investors collectively hold 63.77% of GoodRx's stock, with companies like Allianz Asset Management and SBI Securities increasing their stakes significantly during the same period.
• GoodRx recently reported a quarterly earnings per share of $0.09, exceeding analysts' expectations of $0.04, with a revenue of $202.97 million for the quarter—a 2.6% increase year-over-year.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 62,104 shares of the company's stock, valued at approximately $274,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. grew its position in GoodRx by 303.3% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company's stock worth $4,936,000 after purchasing an additional 798,261 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in GoodRx in the 4th quarter worth about $2,500,000. Vanguard Group Inc. grew its stake in GoodRx by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company's stock valued at $38,935,000 after acquiring an additional 460,753 shares in the last quarter. EVR Research LP acquired a new position in shares of GoodRx in the 4th quarter valued at about $1,761,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of GoodRx by 22.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock worth $9,264,000 after purchasing an additional 369,553 shares during the period. Institutional investors and hedge funds own 63.77% of the company's stock.

GoodRx Stock Performance

GoodRx stock traded up $0.06 during trading hours on Friday, hitting $3.53. The stock had a trading volume of 1,792,563 shares, compared to its average volume of 1,472,656. GoodRx Holdings, Inc. has a fifty-two week low of $3.31 and a fifty-two week high of $8.80. The company has a market cap of $1.26 billion, a PE ratio of 35.25, a price-to-earnings-growth ratio of 1.93 and a beta of 1.24. The company has a 50-day moving average of $4.61 and a two-hundred day moving average of $4.56. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 0.74.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). The business had revenue of $203.07 million for the quarter, compared to the consensus estimate of $205.72 million. GoodRx had a return on equity of 8.71% and a net margin of 4.33%. The firm's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.08 EPS. On average, equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm's stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.53% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on GDRX. Wells Fargo & Company decreased their target price on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. UBS Group dropped their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Truist Financial cut their price target on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a report on Thursday, April 10th. Finally, The Goldman Sachs Group decreased their price target on GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $6.55.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.